Australia markets closed

Becton, Dickinson and Company (BDX)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
234.05+3.35 (+1.45%)
At close: 04:00PM EDT
234.05 0.00 (0.00%)
After hours: 06:16PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close230.70
Open230.55
Bid0.00 x 1400
Ask235.53 x 1000
Day's range229.76 - 235.30
52-week range218.75 - 287.32
Volume1,128,072
Avg. volume1,472,693
Market cap67.642B
Beta (5Y monthly)0.44
PE ratio (TTM)50.01
EPS (TTM)4.68
Earnings date02 May 2024
Forward dividend & yield3.80 (1.62%)
Ex-dividend date10 June 2024
1y target est274.66
  • Zacks

    BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage

    BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.

  • PR Newswire

    BD Statement on Supplier Issue Impacting BD BACTEC™ Blood Culture Vials

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to a U.S. FDA letter to health care providers regarding the supply of blood culture vials:

  • PR Newswire

    BD Surpasses Scope 1 and 2 Reduction Milestones for FY 2023

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has surpassed its Scope 1 and 2 science-based greenhouse gas (GHG) emissions reduction targets for FY 2023 by 5 percentage points and received approval for near and long-term science-based emissions reduction targets from the Science Based Target initiative (SBTi)[1]. This furthers the company's progress toward its goal to reach net zero GHG emissions across its value chain by FY 2050.